LINDSAY PONSTEIN: Open Payments
NPI 1598005522 · SLIDELL, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,575 in 124 payments from 23 companies in 2025. Trend: 2023 $2,560 · 2024 $2,860 · 2025 $2,575
Food & beverage: $2,575
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $345 |
| GlaxoSmithKline, LLC. | 21 | $321 |
| GENZYME CORPORATION | 11 | $309 |
| Regeneron Healthcare Solutions, Inc. | 7 | $269 |
| Merck Sharp & Dohme LLC | 10 | $202 |
| Verona Pharma, Inc. | 9 | $178 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $169 |
| Insmed, Inc. | 6 | $135 |
| Astellas Pharma US Inc | 3 | $95 |
| ABBVIE INC. | 5 | $87 |
Products named: DUPIXENT, Ohtuvayre, TRELEGY ELLIPTA, NUCALA, BREZTRI, Arikayce, PIFELTRO, FASENRA.
Industry payments across LA — which companies pay providers there.
